Compare ZYXI & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYXI | FGEN |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 35.6M |
| IPO Year | N/A | 2014 |
| Metric | ZYXI | FGEN |
|---|---|---|
| Price | $0.74 | $8.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $3.00 | ★ $146.50 |
| AVG Volume (30 Days) | ★ 14.6M | 26.2K |
| Earning Date | 11-17-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | ★ $108,202,000.00 | $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.30 | N/A |
| P/E Ratio | ★ N/A | $0.16 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $4.85 |
| 52 Week High | $8.72 | $21.94 |
| Indicator | ZYXI | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 38.23 |
| Support Level | $0.75 | $7.99 |
| Resistance Level | $0.95 | $9.09 |
| Average True Range (ATR) | 0.29 | 0.37 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 7.48 | 34.82 |
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.